2024
Characterizing the Rise in Dupilumab Prescriptions and Costs: A Medicare Part D Study
Torabi S, Patel R, Bitner B, Manes R, Kuan E. Characterizing the Rise in Dupilumab Prescriptions and Costs: A Medicare Part D Study. Otolaryngology 2024 PMID: 39248223, DOI: 10.1002/ohn.971.Peer-Reviewed Original Research
2021
Animal Models for Otolaryngological Disorders
Doukas S, Bartoshuk L, Manes R, Michaelides E, Santos-Sacchi J, Spock T, Sukys J, Sasaki C. Animal Models for Otolaryngological Disorders. 2021, 775-796. DOI: 10.1201/9780429439964-34.Peer-Reviewed Original Research
2020
Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population
Torabi SJ, Kasle DA, Savoca EL, Gottschalk CH, Manes RP. Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population. Headache The Journal Of Head And Face Pain 2020, 61: 373-384. PMID: 33337542, DOI: 10.1111/head.14040.Peer-Reviewed Original ResearchConceptsAdvanced practice providersHigh-volume providersMedicare populationTreatment modalitiesMedicare patientsPractice providersSubstantial geographic variationMedicare Provider UtilizationProcedure volumeCPT codesPopular treatmentHigher mean numberNeurologistsCross-sectional dataProvider UtilizationMean numberPhysiciansSubstantial proportionChemodenervationReimbursement trendsTreatmentTotal beneficiariesProvidersTotalTotal number
2019
Multi-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors
Torabi SJ, Spock T, Cardoso B, Chao J, Manes RP, Judson BL. Multi-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors. Journal Of Neurological Surgery Part B Skull Base 2019, 81: 198-205. PMID: 32206540, PMCID: PMC7082160, DOI: 10.1055/s-0039-1683437.Peer-Reviewed Original ResearchMinor salivary gland tumorsSalivary gland tumorsTriple-modality therapyGland tumorsModality therapyMultimodality treatmentPositive marginsTreatment modalitiesSubset analysisNational Comprehensive Cancer Network guidelinesClinical American Joint CommitteeNational Cancer DatabaseMulti-modality treatmentOnly treatment modalityAmerican Joint CommitteeMost treatment modalitiesAdjuvant chemoradiotherapySurvival benefitSurgical managementNetwork guidelinesCancer DatabaseChemoradiotherapyCommon treatmentSurgeryJoint Committee
2016
Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma
Kuo P, Manes RP, Schwam ZG, Judson BL. Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma. Otolaryngology 2016, 156: 132-136. PMID: 27703092, DOI: 10.1177/0194599816670146.Peer-Reviewed Original ResearchConceptsSinonasal undifferentiated carcinomaCombined modality therapyNational Cancer DatabaseUndifferentiated carcinomaChemoradiotherapy groupModality therapyOverall survivalSurvival outcomesTreatment modalitiesCancer DatabaseSurvival rateAdjuvant chemotherapy groupImproved survival outcomesMultivariate Cox regressionCumulative survival rateKaplan-Meier analysisMulti-institutional studyCases of SNUCAdjuvant chemotherapyChemotherapy groupMultimodality therapyModality treatmentPrognostic factorsCox regressionAggressive malignancy